Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good to see the bid moving higher!
Sorry I don’t understand your question?
Guys, I wanted to wait until the market closed to share something. I went to the CA website late this afternoon and in a box on the right of the google page there was a marketing company announcing CA IPO in 2020. I almost fell out of my chair. I clicked on the link and it requested my email address which I don’t give out. I left the site but decided to do it. When I went back the ad wasn’t there and I could not find it anywhere but it started me thinking. Why not IPO in Asia and then apply to one of the US exchanges regardless of being able to sell the itbra in the US. There are hundreds of Chinese companies on US exchanges that we cannot purchase there products in the US. Two I have traded successfully over the past year is (LK) Luckin Coffee and IQ. This is a great strategy to raise funds to launch the itbra and related marketing effort in the US once FDA approves without having to add new investors. Again, I cannot verify this but it makes since. Something to consider.
Yes, that was a 100% gain in two days on probable news. Just think what will happen when news comes out. Wow!!
Glad to see some action! It will run on any sign of strength.
The MM’s like to gap this stock in both directions. If buyers show up this could run.
Good action this morning. Like the FDA reference on the CA website.
Boom, added more today. Looking forward to the next update and will continue to add.
The new CA website looks much cleaner and offers direct assistance to potential clients/doctors. They also appears to have updated the video segments. Good to see progress.
Good to see the order option on the website and a marketing operation to promote the itbra. It is the right time and product for breast screening post crisis.
Go to the Get Cyrcadia page and paragraph and read about the launch. Let me know what you think?
I noticed a large buy and prompted me to go looking for some news. I guess someone else saw it first. Anyway have a small 2M position but will add if I see verifiable information.
It looks like Carcadia Asia has launched a new website that allows Doctors to purchase the system. They have also linked up with a marketing firm. Looks like baby steps but at least some amount of progress.
intexp, thanks for sharing. Good to see Cyrcadia getting noticed for their AI. Also, timely.
Why the buying today?
ONE YEAR AGO TODAY:
Reno, Nevada, Feb. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- We are pleased to share current information and developments with our stakeholders and the public, February 19, 2019.
Regarding Lifeline’s investment in Cyrcadia, Inc. (CI), CI’s largest shareholder at approximately 35%, Cyrcadia has reported the resumption of its clinical studies at El Camino Hospital (ECH) in Mountain View, CA. The resumption of the studies is the result of improvements to both the iTBra system (hardware and application interface) and improvement of the underlying predictive analytics. The objective and result of the improvements yield a system capable of acquiring patient data in a far reduced wear time, 6 hours vs. 24 hours, a low energy Bluetooth communications system, and a design of the hardware intended for ease of use comfort and transfer to manufacturing for eventual commercialization.
The design, development and commercial grade improvements have been performed by Jabil, a world leader in medical device design and engineering, under a contract with Cyrcadia’s licensee company, Hong Kong based, Cyrcadia Asia (CA). Cyrcadia Asia is supplying CI with product for the resumption and completion of this round of studies.
CI has recently returned from a site visit at ECH, to “kick off” the study resumption, reporting a very energetic and eager response from the primary investigator and referring physician at the site. Continued enrollment is expected by late March to early April 2019.
Following the enrollment at ECH, CI will then move to continuation of studies at its other clinical site, Ohio State University. Enrollment of both sites, along with the usability improvements to the CDR-100 system (potentially branded the iTBra) is expected to rapidly accelerate enrollment for completion of the study. The statistical requirement for validation of the study is 173 patients. The study has already achieved enrollment and completion of the initial 66 cases with a balance of 107 to complete. CI’s expectation of accelerated enrollment is based on the reduced wear-time along with broader regional outreach at both site locations.
Additionally, CI is preparing for a potential pre-submission meeting with the FDA to ensure regulatory adherence with the intent of achieving marketing clearance. Upon FDA acceptance of the meeting, CI expects to meet with the FDA in approximately 90 days yielding clear guidance for marketing approval.
Cyrcadia is also currently designing a Pilot Program as a usability and market testing study. The strategy is to contract a number of women’s health clinics throughout the US under a similar protocol to the clinical studies, placing the system in physicians’ hands at “real-world” clinics. The objectives are to gauge user feedback and refine the marketing strategy. Though the Pilot Program is being designed, it will not take place until the company has acceptance by the FDA.
The intended result of these activities is to accelerate CI’s drive to possible significant value via generation of revenue by the end of 2019 or early 2020, through sales directly to physician clinics (based on information obtained from the Pilot Program), leading to a possible merger or acquisition potentially some time in 2020. It must be noted that the iTBra system has not yet been cleared by the FDA for marketing in the United State
I have always thought the biggest challenge for getting this to market was managing the tremendous amount of data with zero errors. You cannot make a mistake and send someone an incorrect diagnosis. If this company can manage the data then that’s a huge issue resolved. Like others have said the major players who have invested in Carcadia gives us hope for implementation in the future. When is anyone’s guess. But, worth a bet. It’s only .0014. Bought another 100,000 shares today. If you can’t afford $140.00 bucks then you shouldn’t be allowed on this board.
Grove, IMO JH has little to nothing to do with Cyrcadia. I think he is waiting just like the rest of us. While he certainly knows more than we do he has no authority to release news.
Arnie, I would be happy with a CE or FDA approval. I also believe they are working in India. In my media goggle search today, I saw an article from June in an Indian medical journal describing the Cyrcadia itbra.
Guys,
Cyrcadia keeps getting mentioned as a Major Player in the AI market. This from Market Watch on Nov. 18th...
Nov 18, 2019 (Market Insight Reports via COMTEX) -- Artificial Intelligence (AI) is a highly data-driven technology that is capable of making complex decisions almost in level with human intellectual capabilities. In the life sciences sector, it is often employed to make meaningful relations from loosely coupled data. With the advent of the third wave of AI, it is estimated that advanced AI solutions in the current market scenario can learn and evolve as they are being used. Further, the penetration of AI life sciences solutions into the mobile application sector is expected to be the prime driver of AI solutions in the near future.
Artificial intelligence in life sciences market is expected to grow at a CAGR of over 30% during the forecast period (2018 – 2023).
Get a sample copy of report before purchase:
https://www.marketinsightsreports.com/reports/01241063585/global-artificial-intelligence-in-life-sciences-market-growth-trend-and-forecasts-2018-2023/inquiry?source=MW&mode=10
Some of the major players of the market are:
IBM Corporation, Aicure, Llc, Numedii, Inc., Twoxar, Inc., Atomwise Inc., Lifegraph Limited, Cyrcadia Health Inc, Zebra Medical Vision, Apixio, Inc., Enlitic, Inc., Insilico Medicine, Inc., Numerate, Inc., Sophia Genetics Sa, And Sensely Inc., amongst others.
That’s the under statement of the last five years. “Behind the scenes” I sure hope so.
More importantly Astra can get the FDA and CE approvals. This is an awesome development/collaboration. LLBO and or Cyrcadia should be sharing this news. Why do you think they hate their shareholders so much that they don’t inform us of important corporate developments.
It's good to see Rob is still alive and well in Asia. He is doing a better job explaining Cyrcadia's plans. I still believe that until we get either FDA or CE approval this will tread water.
Arnie, I don't see anything other than a diagram of how to approach the FDA. What am I missing?
Arnie, where is the FDA Map on the Carcadia website. I can't fine it.
I started buying back in today. However, don’t expect news until 2020. My plan is to purchase 5M shares between now and January 1st = to or >.0017.
Until FDA or CE approval I will remain on the sidelines. Glad to buy back in at higher prices. The opportunity cost is too much. Still holding a couple million shares. Hopefully we hear some news this year.
On CNBC’s fast money show tonight they spent the first 10 minutes talking about wearables and health care. Something Apple should be looking into to grow revenue per services. If Cyrcadia would get this device fda approved then this gets bought within a year for big bucks! No doubt.
That makes since.
When did this ever get to 2.5 cents? I've been here a long time and don't remember it ever reaching a penny. Not bashing just wondering if I was asleep at the switch.
Good luck and will be watching.
Guys, I sold 80% of my position in LLBO after holding for seven years in the .0018's. I was hoping that it was a mistake. I guess not given the continued lack of news from Cyrcadia and the decline in the stock price. I really thought this had as good as chance as any long shot sub-penny stock. I don't think it is a scam, but I think the current management isn't up to the task of gaining the necessary approvals. The roll out has been delayed by years, and even with some investment by major players there doesn't seem to be much movement and no updates. I really like the concept but until news on FDA or CE Mark approval, I am going to sell into any strength. I wish you guys well who are holding large positions. I'll keep my eye on it and join back in if there is real news from the company.
GHSI is a good example of what will happen to CA once the device receives approval in Asia. This is for Mead...long and strong...we will miss you my friend.
I have sent an email to Ms. Wong and asked her to consider doing another segment with Rob regarding a six month update on patient/doctor acceptance, data gathering, and is the device working as promised. I'll let you know what I hear. She has always responded to my emails over the past year. So I expect to hear back within the next few days.
Thanks for sharing. Nice to see we are getting national recognition.
Big gap to fill back up to the 7’s. This news should fill that gap quickly. Short squeeze to follow to the 10’s. Then updated status and listing on the big board in the near future. This company is what all pennies hope to be “real” and profit making.
A penny stock with half a billion in signed contracts and growing. Dude this company is going to be bought out. Over .06 tomorrow and .09 on Friday.
Completely agree. Noticed two new Cyrcadia Health team members on the "revised" website. A new medical director and a physician relationship manager. Did someone post that CH USA was meeting with the FDA this month? Thought I saw that...
If you like anniversaries, it was one year ago today, that CH announced it's ItBra launch in Asia. The actual launch took place in Jan. 2019. It would be nice to hear about how patients are accepting this new diagnostic test. Also, how the data processing is working. But, I'm realistic so I'll just wait for FDA approval, CE Mark approval, and/or a partnership arrangement or buyout. Lots to look forward too. The actual timing of any of these outcomes is impossible to predict.
Guys, just had an article posted on my facebook page from a friend who is being treated with radiation for stage 3 breast cancer. The article states that radiation treatments of any kind (breast/dental) are affecting the thyroid gland. Apparently, there is an uptick and link between thyroid cancer and individuals undergoing radiation treatment. This continues to build the case for a non-radiation based exam. This link and the density issues previously discussed sure makes Cyrcadia Health look like a great option for the future.